Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04813107
Title A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jiangsu Yahong Meditech Co., Ltd aka Asieris
Indications

bladder urothelial carcinoma

Therapies

APL-1202 + Tislelizumab

Tislelizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mount Sinai Medical Center Recruiting New York New York 10001 United States Details
Fudan University Shanghai Cancer Center Recruiting Shanghai Shanghai 201203 China Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field